United StatesThe article highlights a personnel change at Delphia Therapeutics, where David Kerstein has been appointed as chief medical officer. Kerstein previously held similar roles at IDRx and Theseus Pharmaceuticals. The piece is part of a recurring feature in which the author, Ed Silverman, profiles individuals in the pharmaceutical industry. The article serves as a professional update rather than a news report, emphasizing career moves within the sector. It includes a call for readers to submit their own updates and offers access to exclusive content through STAT+ subscription.
Lecture du biais (Centre): The article focuses on a personnel change in the pharmaceutical industry, which is a commercial and professional matter rather than a politically charged issue. While prescription drug pricing and related topics can be politically sensitive, the specific content of this article does not take a clear
